Aumenta la fuerza y el rendimiento fsico
Clin Chim Acta 2003
Generally safe to combine, but monitor skin closely for any unexpected changes
Estimating this rather than working out the actual figure makes it difficult to keep dosing consistent across a research timeline, which undermines the reliability of any comparison drawn between sessions

The blots were incubated with the following primary antibodies: GAPDH (1:10,000, Proteintech, 60,0041-Ig), HK2 (1:1000, Abcam, ab209847), TH (1:5000, Abcam, ab137869), LDHA (1:1000, Cell Signaling Technology, 3582S), Bax (1:1000, Abcam, ab32503), Bcl2 (1:1000, Abcam, ab32124), AMPK1/2 (H 300) (1:500, Santa Cruz Biotechnology, sc-25,792), phospho-AMPK1/2 (Thr 183/172) (1:500, Santa Cruz Biotechnology, sc-101,630), phospho-Akt (Thr308) (1:1000, Cell Signaling Technology, 4056S), Akt (1:1000, Cell Signaling Technology, 9272S), phospho-mTOR (Ser2448) (1:1,000, Cell Signaling Technology, 5336S), mTOR (7C10) (1:1000, Cell Signaling Technology, 2983S), -Synuclein (1:1000, Cell Signaling Technology, 4179S), BDNF (1:1000, Abcam, ab108319), PGC-1 (1:100, Abcam, ab191838), PDK1 (1:2000, Abcam, ab202468), PKM2 (1:1000, Cell Signaling Technology, 4053), GPX4 (1:1000, Abcam, ab125066), UCP2 (1:1000, Abcam, 89326), ATP5A (1:1000, Cell Signaling Technology, 18023), UQCRC2 (1:1000, Cell Signaling Technology, 99258), MTCO1 (1:1000, Abcam, ab14705), SIRT1 (1:1000, Abcam, ab110304), HIF-1 (1:1000, Abcam, ab308433), NRF1 (1:1000, Abcam, ab175932), and NRF2 (1:1000, Abcam, ab207223)
